MiniDock MTB Swab Test Meets WHO Accuracy Targets for Tuberculosis

Tuberculosis remains a primary driver of infectious disease mortality worldwide, with 2021 estimates highlighting the persistent challenge of undiagnosed cases across 204 countries and territories [1]. While sputum-based nucleic acid amplification tests (molecular techniques that identify specific genetic sequences of the pathogen) have improved detection, many patients struggle to expectorate the high-quality samples required for these assays [2, 3]. This challenge is particularly acute in pediatric populations and individuals with human immunodeficiency virus (HIV), where low bacterial loads often lead to false-negative results on traditional smear microscopy [4, 5]. Recent meta-analyses indicate that oral swabs, a noninvasive alternative, demonstrate a combined sensitivity of 0.67 and specificity of 0.95 in pulmonary tuberculosis cases [5]. Specifically, tongue swabs have shown a higher sensitivity of 0.75 (95% CI: 0.65 to 0.83) compared to 0.52 (95% CI: 0.34 to 0.70) for cheek specimens [5]. To address this diagnostic gap, a multi-country prospective study now evaluates the diagnostic accuracy and clinical usability of a new molecular system designed for these diverse healthcare environments.